Compare Hilton Hotels Corporation Common Stock (HLT) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hilton Hotels Corporation Common Stock vs Illumina, Inc. — how do they compare? Hilton Hotels Corporation Common Stock trades at $326.32 (market cap $73.63B), while Illumina, Inc. trades at $189.82 (market cap $27.94B). The key difference: Hilton Hotels Corporation Common Stock is far larger — about 2.6× Illumina, Inc.'s market cap, and Hilton Hotels Corporation Common Stock pays a 0.19% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.
| HLT | ILMN | |
|---|---|---|
Market Cap | $73.63B | $27.94B |
Sector | Consumer Cyclical | Health |
52-Week High | $350.22 | $194.33 |
52-Week Low | $256.75 | $91.00 |
Enterprise Value | $86.12B | $29.33B |
Dividend Yield | 0.19% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hilton Worldwide Holdings (HLT) trades at $323.22, up 0.59% with a bearish technical signal despite consistent earnings beats. The company shows strong fundamentals with 2025 revenue of $12.04B and net income of $1.46B, though valuation metrics appear elevated with a P/E of 49.06. Recent developments include brand expansion initiatives and upcoming Q2 2026 earnings on July 28, 2026.
Wall Street maintains a bullish outlook with 55% buy ratings and a $345.18 price target, representing 6.8% upside. Key risks include rising debt levels (debt-to-asset ratio increased to 73.88% in 2025) and technical weakness. The stock offers growth potential through Hilton's brand expansion but faces headwinds from high valuation and negative shareholder equity.
Illumina (ILMN) trades at $185.36, down 0.69% on the day, with a bullish technical signal from moving averages. The stock shows strong profitability with a 19.42% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion of the Billion Cell Atlas program and upcoming Q2 2026 earnings on July 30.
Outlook remains positive with 51% analyst buy ratings, though the current price exceeds the $178 consensus target. Key risks include competitive pressure from Roche's new sequencer and China market weakness. Earnings growth and cost control initiatives support upside potential, but valuation multiples suggest limited near-term appreciation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hilton Hotels Corporation Common Stock
Hilton Worldwide Holdings operates 1,074,791 rooms across its 18 brands addressing the midscale through luxury segments as of Dec. 31, 2021. Hampton and Hilton are the two largest brands by total room count at 28% and 21%, respectively, as of Dec. 31, 2021. Recent brands launched over the last few years include Home2, Curio, Canopy, Tru, and Tempo. Managed and franchised represent the vast majority of adjusted EBITDA, predominantly from the Americas regions.
Read more on HLT →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
